Anti-hormonal Maintenance Treatment With the CDK4/6 Inhibitor Ribociclib After 1st Line Chemotherapy in Hormone Receptor Positive / HER2 Negative Metastatic Breast Cancer: A Phase II Trial
Latest Information Update: 13 Sep 2023
At a glance
- Drugs Ribociclib (Primary) ; Anastrozole; Exemestane; Fulvestrant; Letrozole
- Indications Advanced breast cancer; Carcinoma; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms AMICA
- 06 Jul 2023 Status changed from discontinued to completed.
- 10 Dec 2022 The study was amended after inclusion of 37 patients due to slow accrual.
- 10 Dec 2022 Status changed to discontinued, according to Results presented at the 45th Annual San Antonio Breast Cancer Symposium.